Drugs

, Volume 73, Issue 12, pp 1307–1319 | Cite as

Subcutaneous Immunoglobulin for Primary and Secondary Immunodeficiencies: an Evidence-Based Review

Systematic Review

Abstract

Background

Substitution with immunoglobulin can be administered intravenously (IV) or subcutaneously (SC) to patients with immunodeficiency, but it is not clear which route is to be preferred.

Objective

The aim of this study was to compare IV and SC administration of immunoglobulin regarding efficacy, safety, health-related quality of life and health economics in patients with primary or secondary immunodeficiency.

Method

PubMed and other databases were searched. Reference lists of retrieved articles were scanned and major immunoglobulin producers were contacted for additional articles. Randomized and non-randomized clinical studies that compared SC with IV immunoglobulin substitution in patients with immunodeficiency were included. The validity of the findings in the included studies was evaluated and summarized in accordance with the GRADE approach.

Results

Twenty-five studies were included; two randomized and 17 non-randomized studies of patients with primary immunodeficiency, one non-randomized study of patients with secondary immunodeficiency and five studies of health economics. The quality of evidence as assessed by the GRADE score was found to be moderate or low for all outcomes. Both IV and SC administration of immunoglobulin was found to be highly effective in preventing serious bacterial infections. IgG trough levels were higher with SC immunoglobulin substitution. Both therapy forms were concluded to be safe, as no serious adverse event was reported. Minor adverse events, consisting of local symptoms that were usually mild, were more frequent with SC immunoglobulin substitution. Health-related quality of life improved when patients switched from hospital-based IV immunoglobulin substitution to SC immunoglobulin substitution at home. The studies that evaluated health economics all found that SC administration was considerably more cost effective in comparison with IV immunoglobulin substitution. The main difference was that the number of lost work or school days was lower in patients with SC administration.

Conclusion

Both SC and IV immunoglobulin substitution offer protection from serious bacterial infections and have good safety. On the basis of available studies it is not possible to rate one of the two substitution modes as superior to the other, at least not regarding efficacy and safety. Improvement of health-related quality of life with SC immunoglobulin substitution largely seems to be related to home therapy. Studies including patients with secondary immunodeficiency were few, as were randomized studies of patients with primary immunodeficiency.

References

  1. 1.
    Cohn EJ, Oncley JL, Strong LE, et al. Chemical, clinical, and immunological studies on the products of human plasma fractionation. I. The characterization of the protein fractions of human plasma. J Clin Invest. 1944;23:417–32.PubMedCrossRefGoogle Scholar
  2. 2.
    Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9:722–8.PubMedGoogle Scholar
  3. 3.
    Bruton OC. A decade with agammaglobulinemia. J Pediatr. 1962;60:672–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Record BR, Gunn W, et al. Human gammaglobulin. Br Med J. 1946;1:101.PubMedCrossRefGoogle Scholar
  5. 5.
    Eijkhout HW, van der Meer JW, Kallenberg CG, et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia: a randomized, double-blind, multicenter crossover trial. Ann Intern Med. 2001;135:165–74.PubMedCrossRefGoogle Scholar
  6. 6.
    Ochs HD, Fischer SH, Wedgwood RJ, et al. Comparison of high dose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases. Am J Med. 1984;76:78–82.PubMedCrossRefGoogle Scholar
  7. 7.
    Roifman CM, Levison H, Gelfand EW. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet. 1987;1:1075–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Slade HB. Human immunoglobulins for intravenous use and hepatitis C viral transmission. Clin Diagn Lab Immunol. 1994;1:613–9.PubMedGoogle Scholar
  9. 9.
    Gardulf A, Hammarström L, Smith CI. Home treatment of hypogamma-globulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet. 1991;338:162–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Guidelines for diagnosis and treatment of primary immunodeficiency [in Swedish)], 3rd ed. 2011. http://www.slipi.nu/klinik/Broschyr_Riktlinjer_V3_2011.pdf.
  11. 11.
    Guidelines for diagnosis and treatment of primary immunodeficiency [in Danish], 2nd ed. 2013. ISBN 978-87-92568-01-4 http://www.immundefekt-diagnostik.dk.
  12. 12.
    Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100. doi:10.1371/journal.pmed.1000100.PubMedCrossRefGoogle Scholar
  13. 13.
    Food and Drug Administration. Guidance for industry safety, efficacy, and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency. 2008. http://www.fda.gov/cber/guidelines.htm.
  14. 14.
    Chapel HM. Consensus on diagnosis and management of primary antibody deficiencies. BMJ. 1994;308:581–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. J Clin Immunol. 2004;112:1–7.CrossRefGoogle Scholar
  16. 16.
    Chinen J, Shearer WT. Subcutaneous immunoglobulins: alternative for the hypogammaglobulinemic patient? J Allergy Clin Immunol. 2004;114:934–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Busse J, Hoffman F, Schlieben S, et al. Subcutaneous immunoglobulin substitution in primary B-cell defects. Review of the literature and experiences with 17 patients over a period of 6 years [in German]. Tagliche Praxis. 2005;46:185–92.Google Scholar
  18. 18.
    Chouksey A, Duff K, Wasserbauer N, et al. Subcutaneous immunoglobulin-G replacement therapy with preparations currently available in the United States for intravenous or intramuscular use: reasons and regimens. Allergy Asthma Clin Immunol. 2005;1:120–30.PubMedGoogle Scholar
  19. 19.
    Durandy A, Wahn V, Petteway S, et al. Immunoglobulin replacement therapy in primary antibody deficiency diseases: maximizing success. Int Arch Allergy Immunol. 2005;136:217–29.PubMedCrossRefGoogle Scholar
  20. 20.
    Gardulf A, Nicolay U. Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr Opin Allergy Clin Immunol. 2006;6:434–42.PubMedCrossRefGoogle Scholar
  21. 21.
    Hernandez M, Bastian JF. Immunodeficiency in childhood. Curr Allergy Asthma Rep. 2006;6:468–74.PubMedCrossRefGoogle Scholar
  22. 22.
    Helbert M, Farragher A. Subcutaneous immunoglobulin for patients with antibody deficiency. Br J Hosp Med (Lond). 2007;68:206–10.Google Scholar
  23. 23.
    Ballow M. Immunoglobulin therapy: methods of delivery. J Allergy Clin Immunol. 2008;122:1038–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Berger M. Principles and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin N Am. 2008;28:413–37.CrossRefGoogle Scholar
  25. 25.
    Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin N Am. 2008;28:803–19.CrossRefGoogle Scholar
  26. 26.
    Moore ML, Quinn JM. Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century. Ann Allergy Asthma Immunol. 2008;101:114–21.PubMedCrossRefGoogle Scholar
  27. 27.
    Stiehm ER, Keller MA, Vyas GN. Preparation and use of therapeutic antibodies primarily of human origin. Biologicals. 2008;36:363–74.PubMedCrossRefGoogle Scholar
  28. 28.
    Kirmse J. The nurse’s role in intravenous immunoglobulin therapy. Home Healthc Nurse. 2009;27:104–11.PubMedCrossRefGoogle Scholar
  29. 29.
    Misbah S, Sturzenegger MH, Borte M, et al. Subcutaneous immunoglobulin: opportunities and outlook. Clin Exp Immunol. 2009;158:51–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Moore ML, Quinn JM. Subcutaneous immunoglobulin therapy in pediatric primary antibody deficiency. Ped Health. 2009;3:231–40.CrossRefGoogle Scholar
  31. 31.
    Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol. 2010;125:182–94.CrossRefGoogle Scholar
  32. 32.
    Berger M. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose. Curr Opin Allergy Clin Immunol. 2011;11:532–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Hoernes M, Seger R, Reichenbach J. Modern management of primary B-cell immunodeficiencies. Pediatr Allergy Immunol. 2011;22:758–69.PubMedCrossRefGoogle Scholar
  34. 34.
    Maarschalk-Ellerbroek LJ, Hoepelman IM, Ellerbroek PM. Immunoglobulin treatment in primary antibody deficiency. Int J Antimicrob Agents. 2011;37:396–404.PubMedCrossRefGoogle Scholar
  35. 35.
    Misbah S, Kuijpers T, van der Heijden J, et al. Bringing immunoglobulin knowledge up to date: how should we treat today? Clin Exp Immunol. 2011;166:16–25.PubMedCrossRefGoogle Scholar
  36. 36.
    Rezaei N, Abolhassani H, Aghamohammadi A, et al. Indications and safety of intravenous and subcutaneous immunoglobulin therapy. Expert Rev Clin Immunol. 2011;7:301–16.PubMedCrossRefGoogle Scholar
  37. 37.
    Abolhassani H, Sadaghiani MS, Aghamohammadi A, et al. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol. 2012;32:1180–92.PubMedCrossRefGoogle Scholar
  38. 38.
    Borte M, Baumann U, Pittrow D, et al. Immunoglobulins in PID, SID and neurological autoimmune disease [in German]. Dtsch Med Wochenschr. 2012;137:675–80.PubMedCrossRefGoogle Scholar
  39. 39.
    Haddad E, Barnes D, Kafal A. Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases. Transfus Apher Sci. 2012;46:315–21.PubMedCrossRefGoogle Scholar
  40. 40.
    Hernandez-Trujillo HS, Chapel H, Lo Re V, et al. Comparison of American and European practices in the management of patients with primary immunodeficiencies. Clin Exp Immunol. 2012;169:57–69.PubMedCrossRefGoogle Scholar
  41. 41.
    Kobrinsky L. Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Biologics. 2012;6:277–87.Google Scholar
  42. 42.
    Atkins D, Best D, Briss PA, GRADE Working Group, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490–4.PubMedCrossRefGoogle Scholar
  43. 43.
    Schünemann H, Brożek J, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendation. Version 3.2 (updated March 2009). The GRADE Working Group, 2009. Available from http://www.cc-ims.net/gradepro.
  44. 44.
  45. 45.
  46. 46.
    Checklist from SBU regarding economic studies. Version 2012:1 http://www.sbu.se/upload/ebm/metodbok/Mall_modell_halsoekonomi.pdf. [Accessed 2012 Jan 03].
  47. 47.
    Gardulf A, Andersen V, Björkander J, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet. 1995;345:365–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Gaspar J, Gerritsen B, Jones A. Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch Dis Child. 1998;79:48–51.PubMedCrossRefGoogle Scholar
  49. 49.
    Chapel HM, Spickett GP, Ericson D, et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol. 2000;20:94–100.PubMedCrossRefGoogle Scholar
  50. 50.
    Gardulf A, Nicolay U, Math D, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol. 2004;114:936–42.PubMedCrossRefGoogle Scholar
  51. 51.
    Högy B, Keinecke H, Borte M. Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. Eur J Health Econ. 2005;6:24–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Nicolay U, Kiessling P, Berger M, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunodeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol. 2006;26:65–72.PubMedCrossRefGoogle Scholar
  53. 53.
    Gardulf A, Nicolay U, Asensio O, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies: a prospective, multi-national study. J Clin Immunol. 2006;26:177–85.PubMedCrossRefGoogle Scholar
  54. 54.
    Haddad L, Perrinet M, Parent D, et al. Economic evaluation of at home subcutaneous and intravenous immunoglobulin substitution [in French]. Rev Med Interne. 2006;27:924–6.PubMedCrossRefGoogle Scholar
  55. 55.
    Kittner JM, Grimbacher B, Wulff W, et al. Patients’ attitude to subcutaneous immunoglobulin substitution as home therapy. J Clin Immunol. 2006;26:400–5.PubMedCrossRefGoogle Scholar
  56. 56.
    Ochs HD, Gupta S, Kiessling P, Subcutaneous IgG Study Group, et al. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol. 2006;26:265–73.PubMedCrossRefGoogle Scholar
  57. 57.
    Fasth A, Nyström J. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency. Acta Paediatr. 2007;96:1474–8.PubMedCrossRefGoogle Scholar
  58. 58.
    Fasth A, Nyström J. Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin. J Clin Immunol. 2008;28:370–8.PubMedCrossRefGoogle Scholar
  59. 59.
    Desai SH, Chouksey A, Poll J, et al. Pilot study of equal doses of 10 % IGIV given intravenously or subcutaneously. J Allergy Clin Immunol. 2009;124:854–6.PubMedCrossRefGoogle Scholar
  60. 60.
    Maroto Hernando M, Soler Palacín P, Martin Nalda N, et al. Subcutaneous gammaglobulin in common variable immunodeficiency: first experience in Spain [in Spanish]. An Pediatr 2009;70:111–9.Google Scholar
  61. 61.
    Beauté J, Levy P, Millet V, French PID study group CEREDIH, et al. Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies. Clin Exp Immunol. 2010;160:240–5.PubMedCrossRefGoogle Scholar
  62. 62.
    Hoffmann F, Grimbacher B, Thiel J, et al. Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency. Eur J Med Res. 2010;15:238–45.PubMedGoogle Scholar
  63. 63.
    Shapiro R. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. Clin Immunol. 2010;30:301–7.CrossRefGoogle Scholar
  64. 64.
    Wasserman RL, Irani AM, Tracy J, et al. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10 % caprylate/chromatography purified in patients with primary immunodeficiency disease. Clin Exp Immunol. 2010;161:518–26.PubMedCrossRefGoogle Scholar
  65. 65.
    Jolles S, Bernatowska E, de Gracia J, et al. Efficacy and safety of Hizentra® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. Clin Immunol. 2011;141:90–102.PubMedCrossRefGoogle Scholar
  66. 66.
    Wasserman RL, Melamed I, Kobrynski L, et al. Efficacy, safety, and pharmacokinetics of a 10 % liquid immune globulin preparation (GAMMAGARD LIQUID, 10 %) administered subcutaneously in subjects with primary immunodeficiency disease. J Clin Immunol. 2011;31:323–31.PubMedCrossRefGoogle Scholar
  67. 67.
    Wasserman RL, Melamed I, Nelson RP Jr, et al. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. Clin Pharmacokinet. 2011;50:405–11.PubMedCrossRefGoogle Scholar
  68. 68.
    Sundin M, Nordin K, Jostemyr Y, et al. Subcutaneous IgG replacement after pediatric SCT. Pediatric Transpl. 2012;16:866–71.CrossRefGoogle Scholar
  69. 69.
    Wasserman RL, Melamed I, Stein MR, et al. IGSC, 10 % with rHuPH20 Study Group. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol. 2012;130:951–7.PubMedCrossRefGoogle Scholar
  70. 70.
    Martin A, Lavoie L, Goetghebeur M, et al. Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency. Transfus Med. 2013;23:55–60.PubMedCrossRefGoogle Scholar
  71. 71.
    Ducruet T, Levasseur MC, Des Roches A, et al. Pharmacoeconomic advantages of subcutaneous versus intravenous immunoglobulin treatment in a Canadian pediatric center. J Allergy Clin Immunol. 2013;131:585–7.PubMedCrossRefGoogle Scholar
  72. 72.
    Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the primary immunodeficiency committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117:S525–53.PubMedCrossRefGoogle Scholar
  73. 73.
    Gennery AR, Slatter MA, Grandin L, on behalf of members of European Group for Blood and Marrow Transplantation and European Society for Immunodeficiency, et al. Long term survival and transplantation of haematopoietic stem cells for primary immunodeficiencies: report of the European experience 1968–2005. J Allergy Clin Immunol. 2010;126:602–10.PubMedCrossRefGoogle Scholar
  74. 74.
    Eapen M, Ahn KW, Orchard PJ, et al. Long-term survival and late deaths after hematopoietic cell transplantation for primary immunodeficiency diseases and inborn errors of metabolism. Biol Blood Marrow Transpl. 2012;18:1438–45.CrossRefGoogle Scholar
  75. 75.
    Caress JB, Hobson-Webb L, Passmore LV. Case-control study of thromboembolic events associated with IV immunoglobulin. J Neurol. 2009;256:339–42.PubMedCrossRefGoogle Scholar
  76. 76.
    Al-Riyami AZ, Lee J, Connolly M, et al. Cerebral sinus thrombosis following IV immunoglobulin therapy of immune thrombocytopenia purpura. Pediatr Blood Cancer. 2011;57:157–9.PubMedCrossRefGoogle Scholar
  77. 77.
    FDA Safety Communication: New boxed warning for thrombosis related to human immune globulin products. 2013. http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm355986.htm.
  78. 78.
    European Medicines Agency. Hizentra. Product information. EMEA/H/C/002127-II/0020/G. 2013 http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002127/human_med_001440.jsp&mid=WC0b01ac058001d124.
  79. 79.
    Orange JS, Grossman WJ, Navickis RJ, et al. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol. 2010;137:21–30.PubMedCrossRefGoogle Scholar
  80. 80.
    Orange JS, Belohradsky BH, Berger M, et al. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exp Immunol. 2012;169:172–81.PubMedCrossRefGoogle Scholar
  81. 81.
    Berger M, Jolles S, Orange JS, et al. Bioavailability of IgG administered by the subcutaneous route. J Clin Immunol. 2013;33:984–90.PubMedCrossRefGoogle Scholar
  82. 82.
    Huang F, Feuille E, Cunningham-Rundles C. Home care use of intravenous and subcutaneous immunoglobulin for primary immunodeficiency in the United States. J Clin Immunol. 2013;33:49–54.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.Department of PediatricsHalland HospitalHalmstadSweden
  2. 2.Department of PediatricsUniversity of GothenburgGothenburgSweden

Personalised recommendations